Asia Pac Allergy.  2013 Oct;3(4):249-256. 10.5415/apallergy.2013.3.4.249.

Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective study

• Palabrica
• Kwong SL
• Padua FR

• KMID: 2397302
• DOI: http://doi.org/10.5415/apallergy.2013.3.4.249

Abstract

BACKGROUND
Intravenous immunoglobulin (IVIG) is a biological product with adverse effects that appears to vary considerably among different IVIG preparations.
OBJECTIVES
To describe the adverse events of patients given intravenous immunoglobulin infusions. METHOD: Data was collected on all patients receiving IVIG infusion at a tertiary hospital from January 2001 to December 2010. Descriptive statistics was used.
RESULTS
77 patients (45 males, 32 females) received IVIG infusions. Thirty two percent (n = 25) experienced adverse reactions. The most common indication was Kawasaki disease (85.7%) followed by immunodeficiency disorders (7.8%). Majority of the patients were children, with the highest frequency of infusions among those aged 2 to 8 years old (52%). 36 infusions were associated with occurrence of adverse effects. Fever was the most common adverse event (n = 11, 30.6%), followed by rash (n = 8, 22.2%) and chills (n = 7, 19.4%). Other adverse events were cyanosis (n = 3, 8.3%), hypotension (n = 2, 5.6%), hypothermia (n = 2, 5.6%), irritability (n = 1, 2.8%), vomiting (n = 1, 2.8%), and chest pain (n = 1, 2.8%). Adverse events were observed to occur most frequently within 1 to 6 h from onset of IVIG infusion. Among the various IVIG preparations available locally (Gammagard, Kiovig, Gamimune, Veno-S & IV Globulin S), Gammagard was the brand frequently used (50.7%). It also has the most number of adverse events, with 17 out of 41 (41.5%) infusions resulting in adverse reactions. Most of the reactions occurred with fast infusion rates, and clinical manifestations subsided when the rate of infusion was reduced.
CONCLUSION
In this study, thirty two percent of patients given IVIG infusions experienced adverse events. Fever was the most common manifestation. Symptoms occurred within 1 to 6 h from onset of infusion, were affected by fast infusion rates, and managed by reducing the rate of infusion.

Keyword

Intravenous immunoglobulins; Retrospective study; Side effects

MeSH Terms

Chest Pain
Child
Chills
Cyanosis
Exanthema
Fever
Humans
Hypotension
Hypothermia
Immunoglobulins*
Immunoglobulins, Intravenous
Male
Methods
Mucocutaneous Lymph Node Syndrome
Retrospective Studies*
Tertiary Care Centers
Vomiting
Immunoglobulins
Immunoglobulins, Intravenous

Figure

• 

  Fig. 1 Intravenous immunoglobulin preparations.

Reference

1. IVIG Guideline Development Group of the IVIG Expert Group. Clinical guidelines for the use of intravenous immunoglobulin. 2nd ed. London: Department of Health (UK);2008.

2. Duhem C, Dicato MA, Ries F. Side-effects of intravenous immune globulins. Clin Exp Immunol. 1994; 97:Suppl 1. 79–83.

3. Singh-Grewal D, Kemp A, Wong M. A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions. Arch Dis Child. 2006; 91:651–654.

4. Stiehm ER, Ochs HD, Winkelstein JA. Immunodeficiency disorders: general considerations. In : Stiehm ER, Ochs HD, Winkelstein JA, editors. Immunologic disorders in infants and children. 5th ed. Philadelphia: W.B. Saunders;2004. p. 289–345.

5. Ballow M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol. 2011; 127:315–323.

6. Alejandria MM, Lansang MA, Dans LF, Mantaring JB. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev. 2002; CD001090.

7. Dashti-Khavidaki S, Aghamohammadi A, Farshadi F, Movahedi M, Parvaneh N, Pouladi N, Moazzami K, Cheraghi T, Mahdaviani SA, Saghafi S, Heydari G, Abdollahzade S, Rezaei N. Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases. J Investig Allergol Clin Immunol. 2009; 19:139–145.

8. Purisima BC, Garcia RD, Leus A. A retrospective study on the efficacy of Gammagard S/D IVIG versus Vizcarra IVIG in the treatment of Kawasaki disease in Makati Medical Center from 1998-2003. Philippine J Pediatr. 2009; 57:11–16.

9. Lemm G. Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy. Neurology. 2002; 59:S28–S32.

10. Scheinfeld NS, Godwin JE. Intravenous immunoglobulin [Internet]. New York: Medscape from WebMD;c1994. updated 2010 Sep 22. cited 2011 Jan 14. Available from: http://emedicine.medscape.com/article/210367-overview.